Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: gout flare

Considering Benzbromarone as First-Line Therapy for Gout

Arthritis & Rheumatology  |  December 1, 2022

In this comparative effectiveness clinical trial, Yan et al. set out to compare nontitrated, low-dose benzbromarone (not approved in the U.S.), a renal urate transporter 1 inhibitor, with low-dose febuxostat as the first-line therapy in gout patients with renal uric acid underexcretion.

Filed under:ConditionsDrug UpdatesGout and Crystalline ArthritisResearch Rheum Tagged with:Arthritis & RheumatologybenzbromaroneFebuxostatGouthyperuricemiaResearch

Is Gout an Autoinflammatory Syndrome After All?

Jason Liebowitz, MD, FACR  |  November 29, 2022

PHILADELPHIA—The term autoinflammatory syndrome was coined by Daniel L. Kastner, MD, PhD, National Institutes of Health (NIH), Bethesda, Md., not long after he discovered that mutations in the gene MEFV, which codes for the protein pyrin, are responsible for familial Mediterranean fever (FMF).1 Early on, the term was meant to signify monogenic conditions in which…

Filed under:ACR ConvergenceConditionsGout and Crystalline ArthritisMeeting Reports Tagged with:ACR Convergence 2022ACR Convergence 2022 – GoutGout

Gout Research at a Glance

Lisa Stamp, MBChB, FRACP, PhD  |  November 28, 2022

PHILADELPHIA—Approximately 60 research abstracts on gout were accepted for presentation at ACR Convergence 2022, including two plenary abstract presentations. It is exciting to see a wealth of research on gout being undertaken worldwide. Here, we highlight important points from seven of these studies. 1. Abstract 1810: Frequency and Patterns of Opioid Use in the Management…

Filed under:ConditionsGout and Crystalline ArthritisMeeting ReportsResearch Rheum Tagged with:ACR Convergence 2022ACR Convergence 2022 – Gout

Options for Refractory Gout, ILD & More

Ruth Jessen Hickman, MD  |  November 18, 2022

PHILADELPHIA—At the first Plenary Session of ACR Convergence 2022, on Saturday, Nov. 12, speakers shared key research findings on the efficacy and safety of methotrexate as a co-therapy with pegloticase in refractory gout, the effectiveness of rituximab and cyclophosphamide in connective tissue disease associated-interstitial lung disease and the value of remote education for primary care…

Filed under:ConditionsGout and Crystalline ArthritisOther Rheumatic ConditionsSystemic Sclerosis Tagged with:ACR Convergence 2022ACR Convergence 2022 – Gout

Gout Is an Autoinflammatory Metabolic Disease

From the College  |  October 10, 2022

On Monday, Nov. 14, Michael Pillinger, MD, will moderate the session Gout Is an Autoinflammatory Metabolic Disease at ACR Convergence 2022. This session will address the autoinflammatory nature of gout and highlight it as an IL-1β-mediated diseases. Increasing knowledge on the inflammatory mechanisms of gout has implications for disease management. These engaging talks will review…

Filed under:ACR ConvergenceMeeting Reports Tagged with:ACR Convergence 2022ACR Convergence 2022 – Gout

Lost and found

Understanding the Role of Uric Acid in Gout

Ruth Jessen Hickman, MD  |  September 6, 2022

From the first substantial argument in the 19th century that uric acid played a role in gout, it took about 100 years for the medical community to accept its role in triggering acute inflammatory gout attacks. Two papers, both published in 1962, helped demonstrate the link between uric acid and acute gout attacks, quickly opening…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:GoutGout Resource CenterLost & FoundUric acid

Refractory Gout Is a Myth: Tips from an Expert

Samantha C. Shapiro, MD  |  July 22, 2022

At this EULAR 2022 session, one expert explains why he believes refractory gout is caused by mismanagement and discussed ways around treatment obstacles.

Filed under:ConditionsEULAR/OtherGout and Crystalline ArthritisMeeting Reports Tagged with:EULARGoutGout Resource Centerpatient carerefractory gout

Imaging Modalities in Gout: How to Use them in Clinical Practice

Samantha C. Shapiro, MD  |  July 21, 2022

This EULAR 2022 session discussed the increasing role of imaging in the diagnosis of gout.

Filed under:ConditionsEULAR/OtherGout and Crystalline ArthritisMeeting Reports Tagged with:DECTdual-energy computed tomography (DECT)EULARGoutGout Resource Centerimagingmonosodium urate crystalsUltrasound

Treating to Target in Gout: The Trouble with Serum Urate

Samantha C. Shapiro, MD  |  July 21, 2022

New analyses of treat to target in gout may lead to revisions in some guidelines.

Filed under:ConditionsEULAR/OtherGout and Crystalline ArthritisMeeting Reports Tagged with:EULARGoutGout Resource CenterTreat-to-Target

Gout Experts Share Insights Into a Variety of Challenging Gout Scenarios

Ruth Jessen Hickman, MD  |  June 14, 2022

Although the diagnosis and treatment of gout are sometimes straightforward, prac­titioners encounter challenges in patients with atypical presentations, as well as those with medically complex situations or refractory disease. Here, gout experts share insights into some of these scenarios. Flare in Hospitalized Patients When not contraindicated, the 2020 ACR Guideline for the Management of Gout…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:Flaresorgan transplantpegloticasepolyarticular arthritisrefractory gout

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 17
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences